Pfizer to ax 1,100 R&D jobs in eastern Connecticut

Feb 01, 2011

(AP) -- Pfizer Inc. says it will lay off more than 1,000 employees at its Groton research and development site as the drug giant cuts costs.

Spokesman Mackay Jimeson (JIM'-eh-sin) said Pfizer's announcement Tuesday was part of its strategy to focus on neuroscience, oncology and other areas and to boost productivity. Research and development costs will be cut by up to $2 billion by 2012.

The Groton work force of 4,500 will be cut to about 3,400 in the next 18 months. Jimeson says it will still be Pfizer's largest research and development site.

Jimeson also confirmed that will quit a center in southern England in the next 18 months to two years.

Explore further: Hormonal therapy for transsexualism safe and effective

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer drug found with serious side effect

Nov 01, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

FDA approves larger dose of Pfizer's Aricept

Jul 25, 2010

(AP) -- Drugmakers Eisai Inc. and Pfizer Inc. said on Saturday that government regulators have given them permission to make a larger dose of its Alzheimer's disease drug Aricept for patients who have already been taking ...

Free Lipitor, Viagra, other drugs for jobless

May 14, 2009

(AP) -- Pfizer Inc. is unveiling a new program Thursday that will let people who have lost their jobs and health insurance keep taking some widely prescribed Pfizer medications - including Lipitor and Viagra ...

NIH scientist is under investigation

Jun 13, 2006

A U.S. House committee is reportedly investigating whether a senior government scientist improperly gave information to a pharmaceutical firm.

Recommended for you

Hormonal therapy for transsexualism safe and effective

12 hours ago

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

15 hours ago

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments : 0

More news stories

Aspirin may fight cancer by slowing DNA damage

Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells ...

3D printing tiny batteries

(Phys.org) —3D printing can now be used to print lithium-ion microbatteries the size of a grain of sand. The printed microbatteries could supply electricity to tiny devices in fields from medicine to communications, ...